Mechanism of action
Buprenorphine is a partial agonist at the μ-opioid receptor and an antagonist at the κ-opioid receptor. As a partial agonist, it binds with very high affinity to μ-receptors but produces submaximal receptor activation compared to full agonists like morphine or heroin.
This partial agonism creates a ceiling effect for both analgesia and respiratory depression. Beyond a certain dose, increasing the amount of buprenorphine does not produce additional euphoria or further respiratory depression, which significantly reduces overdose risk compared to full opioid agonists. The ceiling for respiratory depression occurs at lower doses than the ceiling for analgesia, providing a therapeutic safety margin.
Buprenorphine has extremely high receptor affinity (greater than morphine or fentanyl) and dissociates very slowly from μ-receptors, with a dissociation half-life of approximately 166 minutes. This tight binding and slow dissociation explain its long duration of action and ability to block the effects of subsequently administered full agonists. It can precipitate withdrawal in opioid-dependent patients by displacing full agonists from receptors while providing only partial activation.
The κ-opioid antagonist activity may contribute to antidepressant and anti-dysphoric effects and reduce the psychotomimetic effects seen with some mixed agonist-antagonist opioids.
- Buprenorphine is a partial μ-opioid agonist with a ceiling effect for respiratory depression, making it safer than full agonists in overdose.
- High receptor affinity and slow dissociation can precipitate withdrawal if given to opioid-dependent patients before they are in withdrawal.
- Combination with benzodiazepines carries a black box warning due to risk of fatal respiratory depression despite buprenorphine's ceiling effect.
- Naloxone in buprenorphine-naloxone products is poorly absorbed sublingually but active if injected, deterring IV misuse.
- Metabolized by CYP3A4; strong inhibitors increase levels (risk of toxicity) and inducers decrease levels (risk of withdrawal).
- Patients should be in moderate withdrawal (COWS ≥8-12) before buprenorphine induction to avoid precipitated withdrawal.
- Long elimination half-life (24-42 hours) allows once-daily or less frequent dosing in opioid use disorder treatment.
- High receptor affinity blocks effects of subsequently administered full agonist opioids, complicating acute pain management.
Indications
Opioid use disorder (OUD)
Buprenorphine is a first-line medication-assisted treatment (MAT) for OUD. It suppresses withdrawal symptoms and cravings while blocking the euphoric effects of illicit opioids. Formulations include sublingual tablets and films (often combined with naloxone to deter intravenous misuse), long-acting subcutaneous injections, and subdermal implants. The naloxone component in combination products (e.g., buprenorphine-naloxone) is poorly absorbed sublingually but becomes active if injected, precipitating withdrawal and discouraging diversion.
Pain management
Buprenorphine is used for moderate to severe pain, particularly chronic pain. Available formulations include transdermal patches for continuous analgesia and buccal films. The analgesic ceiling effect limits its use in acute severe pain but provides safety advantages in outpatient chronic pain management.
Other uses
Low-dose buprenorphine is being investigated for treatment-resistant depression, though this remains off-label. It is occasionally used as a bridge therapy when transitioning patients between opioid regimens.
Pharmacokinetics
Absorption and bioavailability
Buprenorphine undergoes extensive first-pass metabolism, resulting in very low oral bioavailability (approximately 10%). Sublingual administration bypasses first-pass metabolism, achieving bioavailability of 30-50%. Transdermal and buccal formulations provide alternative routes. Peak plasma concentrations occur 1-4 hours after sublingual dosing.
Distribution
Buprenorphine is highly lipophilic and has a large volume of distribution (approximately 430 L). It is approximately 96% protein-bound, primarily to α- and β-globulin. The drug crosses the blood-brain barrier readily and also crosses the placenta.
Metabolism
Buprenorphine is metabolized primarily by CYP3A4 via N-dealkylation to norbuprenorphine, which has some opioid activity but less than the parent compound. Both buprenorphine and norbuprenorphine undergo glucuronidation. The drug undergoes extensive enterohepatic recirculation, contributing to its long duration of action.
Elimination
Approximately 70% of buprenorphine is eliminated in feces (primarily as metabolites) and 30% in urine. The elimination half-life is long and variable, ranging from 24-42 hours for sublingual formulations, allowing for once-daily or even less frequent dosing in OUD treatment. The long half-life reflects slow dissociation from opioid receptors and tissue redistribution rather than slow metabolic clearance. Hepatic impairment significantly affects clearance, while renal impairment has minimal impact.
Adverse effects
Common adverse effects
- Constipation (most common chronic effect)
- Nausea and vomiting
- Headache
- Drowsiness and sedation
- Dizziness
- Sweating
- Insomnia
- Dry mouth
Respiratory depression
Buprenorphine causes less respiratory depression than full μ-agonists due to its ceiling effect. However, respiratory depression can occur, particularly when combined with central nervous system depressants (benzodiazepines, alcohol). Fatalities have been reported with buprenorphine-benzodiazepine combinations.
Precipitated withdrawal
In opioid-dependent patients currently using full agonists, buprenorphine can precipitate acute withdrawal by displacing the full agonist from receptors while providing only partial activation. Patients should be in mild to moderate withdrawal (COWS score ≥8-12) before initiating buprenorphine to minimize this risk.
Hepatotoxicity
Elevated liver enzymes and hepatitis have been reported, particularly in patients with pre-existing liver disease or concurrent hepatitis C infection. Baseline and periodic liver function monitoring is recommended.
QTc prolongation
Buprenorphine can prolong the QT interval in a dose-dependent manner, particularly at higher doses used for pain management. The risk is lower than with methadone but warrants ECG monitoring in at-risk patients.
Other notable effects
- Hypotension and orthostatic hypotension
- Miosis (pupil constriction)
- Urinary retention
- Decreased libido and hypogonadism with chronic use
- Neonatal opioid withdrawal syndrome in infants born to mothers on maintenance therapy
Contraindications and warnings
Absolute contraindications
- Hypersensitivity to buprenorphine or formulation components
- Acute severe bronchial asthma or respiratory depression in unmonitored settings
- Paralytic ileus
Black Box Warnings
The FDA includes black box warnings for: (1) risk of addiction, abuse, and misuse; (2) life-threatening respiratory depression, especially with concomitant benzodiazepines or CNS depressants; (3) accidental exposure in children can be fatal; (4) neonatal opioid withdrawal syndrome; (5) for the extended-release subcutaneous injection formulation (Sublocade), serious harm or death can result from intravenous administration due to formation of a solid mass that can cause vascular occlusion or fatal embolus.
Special populations
Pregnancy: Buprenorphine is FDA Pregnancy Category C (risk cannot be ruled out). For pregnant patients with OUD, buprenorphine maintenance is preferred over withdrawal or continued illicit use, as it improves maternal and fetal outcomes. Neonatal opioid withdrawal syndrome occurs but is typically milder and shorter than with methadone. Mono-product buprenorphine (without naloxone) is preferred during pregnancy.
Lactation: Buprenorphine is excreted in breast milk in small amounts. Breastfeeding is generally not contraindicated and may reduce severity of neonatal withdrawal syndrome.
Hepatic impairment: Use with caution and consider dose reduction. Buprenorphine is contraindicated in severe hepatic impairment for some formulations.
Renal impairment: Dose adjustment is generally not required, but caution is advised.
Elderly: Increased sensitivity to opioid effects; initiate at lower doses.
Warnings
- Risk of opioid withdrawal if administered to dependent patients too soon after last full agonist use
- Adrenal insufficiency with prolonged use
- May impair mental and physical abilities; caution with driving and operating machinery
- Risk of severe hypotension in ambulatory patients
- Use caution in head injury, increased intracranial pressure, or conditions where respiratory drive is compromised
- Hepatotoxicity: monitor liver function, especially in patients with pre-existing hepatic disease or hepatitis C
Drug interactions
CYP3A4 inhibitors
Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, itraconazole) increase buprenorphine levels and may enhance opioid effects including sedation and respiratory depression. Dose reduction of buprenorphine may be necessary. Moderate inhibitors (erythromycin, fluconazole, diltiazem, verapamil) also increase exposure to a lesser degree.
CYP3A4 inducers
Strong inducers (rifampin, carbamazepine, phenytoin, St. John's wort) decrease buprenorphine levels and may precipitate withdrawal symptoms or reduce efficacy in OUD treatment or analgesia. Dose increases may be needed, and alternative agents should be considered.
Central nervous system depressants
Concomitant use with benzodiazepines, alcohol, other opioids, sedatives, hypnotics, muscle relaxants, general anesthetics, antipsychotics, or other CNS depressants increases risk of profound sedation, respiratory depression, coma, and death. This combination carries a black box warning. If concurrent use is necessary, use the lowest effective doses and monitor closely. Many fatal overdoses involve buprenorphine combined with benzodiazepines.
Serotonergic drugs
Combination with SSRIs, SNRIs, TCAs, triptans, MAOIs, or other serotonergic agents may increase risk of serotonin syndrome, though this is rare with buprenorphine.
Anticholinergic drugs
Combination may increase risk of urinary retention and severe constipation, potentially leading to paralytic ileus.
Naltrexone and naloxone
Opioid antagonists can precipitate acute withdrawal in patients on buprenorphine. Conversely, buprenorphine's high receptor affinity means it can block the therapeutic effects of full agonist opioids, complicating acute pain management. Patients requiring emergency analgesia may need higher doses of full agonists, regional anesthesia, or non-opioid analgesics.
Other interactions
- Class IA and III antiarrhythmics and other QT-prolonging drugs may have additive effects on QTc interval
- Muscle relaxants: enhanced neuromuscular blocking effects
- Diuretics: opioids may reduce efficacy by inducing ADH release
Clinical pearls
Induction timing is critical. Patients must be in objective opioid withdrawal (COWS ≥8-12) before starting buprenorphine to avoid precipitated withdrawal. For short-acting opioids, wait 12-24 hours; for long-acting opioids like methadone, wait 24-72 hours or longer. Microdosing protocols are emerging for difficult transitions.
Ceiling effect confers safety. The respiratory depression ceiling makes buprenorphine safer in overdose than full agonists. However, deaths still occur, especially when combined with benzodiazepines or alcohol, which do not have a ceiling effect.
Naloxone is a deterrent, not a blocker. The naloxone in combination products like Suboxone is poorly absorbed sublingually and is included primarily to discourage IV abuse. When injected, naloxone precipitates withdrawal. The naloxone does not interfere with sublingual buprenorphine's therapeutic effects.
Long-acting formulations improve adherence. Monthly depot injections and 6-month subdermal implants eliminate daily dosing, reduce diversion risk, and improve treatment retention in OUD.
Blocking effect complicates acute pain management. Buprenorphine's high receptor affinity means it blocks other opioids for 24-72 hours. For surgery or acute pain, options include continuing buprenorphine and adding short-acting opioids at higher doses, splitting buprenorphine into TID-QID dosing for analgesia, or temporarily transitioning to short-acting full agonists under close supervision.
Lower abuse potential than full agonists. Buprenorphine is Schedule III (US) due to lower euphoria and self-administration compared to Schedule II full agonists, though diversion still occurs.
Office-based treatment is permitted. In the US, clinicians can prescribe buprenorphine for OUD in office settings after completing required training and obtaining a waiver (X-waiver), though recent regulations have relaxed some requirements to expand access.
Urine drug screens require specific testing. Standard opioid immunoassays typically do not detect buprenorphine; specific testing for buprenorphine and norbuprenorphine is needed to confirm adherence.
Pregnancy and OUD. Buprenorphine is preferred over methadone for many pregnant patients with OUD due to comparable efficacy, less neonatal withdrawal, and greater accessibility. Mono-product buprenorphine (without naloxone) is preferred, though evidence suggests the combination product is also safe.
CEILING for buprenorphine safety: Ceiling effect (respiratory depression), Elimination slow (long half-life), Induction requires withdrawal, Liver metabolism (CYP3A4), Inhibits full agonists (high affinity), Naloxone added (deters IV use), Good for OUD (first-line MAT).
Practice questions
1. A 28-year-old man with opioid use disorder presents to the clinic for buprenorphine induction. He last used heroin 8 hours ago. On examination, he appears comfortable with normal vital signs, clear speech, and no diaphoresis or piloerection. His pupils are 4 mm and reactive. Which of the following is the most appropriate next step?
2. A 45-year-old woman on buprenorphine-naloxone maintenance therapy for 6 months is scheduled for elective cholecystectomy. She takes 16 mg sublingual daily and reports good control of cravings. The anesthesiologist is concerned about perioperative pain management. Which of the following strategies is most appropriate?
3. A 32-year-old man presents to the emergency department with altered mental status. His wife reports he takes buprenorphine for opioid use disorder and alprazolam for anxiety. On examination, he is somnolent with respiratory rate of 6 breaths per minute, oxygen saturation 84% on room air, and pinpoint pupils. Which of the following best explains his clinical presentation?
Frequently asked questions
How does buprenorphine work?
Buprenorphine is a partial agonist at μ-opioid receptors and an antagonist at κ-opioid receptors. Its partial agonist activity produces a ceiling effect, meaning that beyond a certain dose, increased amounts do not produce additional euphoria or respiratory depression. This makes it safer than full opioid agonists. Its high receptor affinity and slow dissociation allow it to block the effects of other opioids, suppress cravings and withdrawal, and provide long-lasting analgesia with once-daily or less frequent dosing.
What are the side effects of buprenorphine?
Common side effects include constipation, nausea, headache, drowsiness, dizziness, sweating, and insomnia. More serious adverse effects include respiratory depression (especially when combined with benzodiazepines or alcohol), precipitated withdrawal if given too soon after full agonist use, elevated liver enzymes and hepatotoxicity, QTc prolongation, and hypotension. Chronic use can cause hypogonadism and decreased libido. Neonatal opioid withdrawal syndrome occurs in infants born to mothers on buprenorphine maintenance therapy.
Is buprenorphine a controlled substance?
Yes, buprenorphine is a Schedule III controlled substance in the United States. It has a lower potential for abuse compared to Schedule II opioids like morphine or oxycodone due to its partial agonist activity and ceiling effect for euphoria. However, it still carries risk of misuse, diversion, and physical dependence. Clinicians prescribing buprenorphine for opioid use disorder must follow specific regulations, though recent changes have expanded access to treatment.
Buprenorphine vs methadone — what is the difference?
Buprenorphine is a partial μ-opioid agonist with a ceiling effect for respiratory depression, while methadone is a full μ-agonist without a ceiling, making buprenorphine safer in overdose. Buprenorphine can be prescribed in office settings, whereas methadone for OUD requires dispensing through specialized opioid treatment programs with daily observed dosing initially. Buprenorphine has a faster induction process but requires patients to be in withdrawal before starting. Methadone has greater QTc prolongation risk. Both are effective for opioid use disorder, but buprenorphine offers greater accessibility and flexibility.
Can you take buprenorphine while pregnant?
Yes, buprenorphine is considered safe and is recommended for pregnant patients with opioid use disorder. Continuing buprenorphine maintenance therapy during pregnancy improves maternal and fetal outcomes compared to withdrawal or continued illicit opioid use. Mono-product buprenorphine (without naloxone) is preferred, though combination products have also been used safely. Neonatal opioid withdrawal syndrome occurs in most exposed infants but is typically milder and shorter in duration than with methadone. Breastfeeding is generally encouraged in mothers on stable buprenorphine therapy.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N02AE01WHO ATC/DDD index: N07BC01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.